S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
S&P 500   4,210.24 (+2.13%)
DOW   33,309.51 (+1.63%)
QQQ   325.93 (+2.79%)
AAPL   169.24 (+2.62%)
MSFT   289.16 (+2.43%)
META   178.34 (+5.82%)
GOOGL   119.70 (+2.63%)
AMZN   142.69 (+3.53%)
TSLA   883.07 (+3.89%)
NVDA   180.97 (+5.92%)
NIO   20.05 (+4.59%)
BABA   92.43 (+1.36%)
AMD   99.05 (+3.67%)
MU   61.40 (+3.80%)
T   18.01 (-0.50%)
CGC   3.29 (+14.63%)
GE   77.14 (+2.95%)
F   15.50 (+2.04%)
DIS   112.43 (+3.98%)
AMC   23.67 (+5.43%)
PYPL   98.91 (+4.69%)
PFE   49.95 (+0.34%)
NFLX   244.11 (+6.16%)
NYSE:MCK

McKesson - MCK Stock Forecast, Price & News

$359.61
+4.84 (+1.36%)
(As of 08/10/2022 12:00 AM ET)
Add
Compare
Today's Range
$355.04
$359.97
50-Day Range
$300.57
$354.77
52-Week Range
$193.89
$359.96
Volume
951,011 shs
Average Volume
1.16 million shs
Market Capitalization
$51.69 billion
P/E Ratio
38.01
Dividend Yield
0.53%
Price Target
$335.85

McKesson MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
6.1% Downside
$337.62 Price Target
Short Interest
Healthy
1.46% of Float Sold Short
Dividend Strength
Strong
Based on Four Factors
Sustainability
-1.01
Upright™ Environmental Score
News Sentiment
0.40mentions of McKesson in the last 14 days
Based on 42 Articles This Week
Insider Trading
Selling Shares
$21.98 M Sold Last Quarter
Proj. Earnings Growth
4.93%
From $24.33 to $25.53 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.72 out of 5 stars

Medical Sector

162nd out of 1,108 stocks

Drugs, Proprietaries, & Sundries Industry

3rd out of 7 stocks

MCK stock logo

About McKesson (NYSE:MCK) Stock

McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: U.S. Pharmaceutical, International, Medical-Surgical Solutions, and Prescription Technology Solutions (RxTS). The U.S. Pharmaceutical segment distributes branded, generic, specialty, biosimilar, and over-the-counter pharmaceutical drugs and other healthcare-related products. This segment also provides practice management, technology, clinical support, and business solutions to community-based oncology and other specialty practices; and consulting, outsourcing, technological, and other services, as well as sells financial, operational, and clinical solutions to pharmacies. The International segment offers distribution and services to wholesale, institutional, and retail customers in 13 European countries and Canada. The Medical-Surgical Solutions segment provides medical-surgical supply distribution, logistics, and other services to healthcare providers. The RxTS segment serves biopharma and life sciences partners and patients to address medication challenges for patients throughout their journeys; connects pharmacies, providers, payers, and biopharma companies to deliver innovative access and adherence solutions; and provides third-party logistics and wholesale distribution support solutions. McKesson Corporation was founded in 1833 and is headquartered in Irving, Texas.

McKesson Trading Up 2.1 %

McKesson stock opened at $354.77 on Wednesday. The company has a market cap of $50.99 billion, a P/E ratio of 37.50, a price-to-earnings-growth ratio of 1.43 and a beta of 0.63. McKesson has a 1-year low of $192.38 and a 1-year high of $358.64. The company has a fifty day simple moving average of $324.85 and a 200 day simple moving average of $307.94.

McKesson Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, October 3rd. Stockholders of record on Thursday, September 1st will be given a $0.54 dividend. This represents a $2.16 dividend on an annualized basis and a dividend yield of 0.61%. The ex-dividend date of this dividend is Wednesday, August 31st. This is an increase from McKesson's previous quarterly dividend of $0.47. McKesson's dividend payout ratio (DPR) is 19.87%.

Analyst Ratings Changes

Several equities research analysts have weighed in on MCK shares. UBS Group increased their target price on shares of McKesson from $380.00 to $400.00 and gave the stock a "buy" rating in a report on Thursday, August 4th. Mizuho increased their price objective on shares of McKesson from $331.00 to $345.00 and gave the stock a "neutral" rating in a research report on Thursday, August 4th. Deutsche Bank Aktiengesellschaft increased their price objective on shares of McKesson from $378.00 to $409.00 in a research report on Monday. Morgan Stanley increased their price objective on shares of McKesson from $292.00 to $370.00 and gave the stock an "overweight" rating in a research report on Tuesday, April 12th. Finally, Cowen increased their price objective on shares of McKesson from $325.00 to $361.00 and gave the stock an "outperform" rating in a research report on Monday, April 18th. Two equities research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $337.62.

Insider Activity

In other news, CEO Brian S. Tyler sold 8,678 shares of McKesson stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $331.43, for a total value of $2,876,149.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CEO Brian S. Tyler sold 8,678 shares of McKesson stock in a transaction dated Tuesday, May 17th. The shares were sold at an average price of $331.43, for a total value of $2,876,149.54. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Brian S. Tyler sold 1,535 shares of McKesson stock in a transaction dated Tuesday, June 21st. The shares were sold at an average price of $305.20, for a total transaction of $468,482.00. Following the completion of the transaction, the chief executive officer now directly owns 75,737 shares of the company's stock, valued at approximately $23,114,932.40. The disclosure for this sale can be found here. Insiders sold a total of 58,512 shares of company stock valued at $19,103,825 in the last quarter. Company insiders own 0.21% of the company's stock.

Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

MCK Stock News Headlines

States reach deal over marketing, safety of generic opioids
A former opioid manufacturer is agreeing in principle to pay up to $2.4 billion in a deal with a dozen states over its marketing and product safety practices
West Virginia officials to appeal opioid lawsuit decision
Officials in a West Virginia county plan to appeal a federal judge’s ruling in favor of three major U.S. drug distributors in a landmark lawsuit that accused them of causing a health crisis by distributing 81 million pills over eight years
McKesson (NYSE:MCK) Price Target Raised to $400.00
Mizuho Raises McKesson (NYSE:MCK) Price Target to $345.00
What 6 Analyst Ratings Have To Say About McKesson
McKesson (MCK) Tops Q1 Earnings and Revenue Estimates
See More Headlines
Receive MCK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for McKesson and its competitors with MarketBeat's FREE daily newsletter.

MCK Company Calendar

Last Earnings
10/31/2021
Ex-Dividend for 7/1 Dividend
5/31/2022
Dividend Payable
7/01/2022
Today
8/10/2022
Ex-Dividend for 10/3 Dividend
8/31/2022
Dividend Payable
10/03/2022
Next Earnings (Estimated)
11/07/2022
Fiscal Year End
3/31/2023

Industry, Sector and Symbol

Industry
Drugs, proprietaries, & sundries
Sub-Industry
Health Care Distributors
Sector
Medical
CUSIP
58155Q10
Employees
75,000
Year Founded
1833

Price Target and Rating

Average Stock Price Forecast
$337.62
High Stock Price Forecast
$409.00
Low Stock Price Forecast
$230.00
Forecasted Upside/Downside
-6.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
12 Analysts

Profitability

Net Income
$1.11 billion
Pretax Margin
0.88%

Debt

Sales & Book Value

Annual Sales
$263.97 billion
Cash Flow
$32.72 per share
Book Value
($12.33) per share

Miscellaneous

Free Float
143,428,000
Market Cap
$51.69 billion
Optionable
Optionable
Beta
0.63

Social Links















MCK Stock - Frequently Asked Questions

Should I buy or sell McKesson stock right now?

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for McKesson in the last year. There are currently 2 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MCK shares.
View MCK analyst ratings
or view top-rated stocks.

What is McKesson's stock price forecast for 2022?

12 Wall Street research analysts have issued 1 year price targets for McKesson's stock. Their MCK share price forecasts range from $230.00 to $409.00. On average, they predict the company's share price to reach $337.62 in the next year. This suggests that the stock has a possible downside of 5.8%.
View analysts price targets for MCK
or view top-rated stocks among Wall Street analysts.

How have MCK shares performed in 2022?

McKesson's stock was trading at $248.57 at the start of the year. Since then, MCK stock has increased by 44.1% and is now trading at $358.25.
View the best growth stocks for 2022 here
.

When is McKesson's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, November 7th 2022.
View our MCK earnings forecast
.

How were McKesson's earnings last quarter?

McKesson Co. (NYSE:MCK) issued its earnings results on Sunday, October, 31st. The company reported $6.15 EPS for the quarter, topping the consensus estimate of $4.66 by $1.49. The business earned $66.58 billion during the quarter, compared to analyst estimates of $63.23 billion. McKesson had a negative trailing twelve-month return on equity of 350.22% and a net margin of 0.52%. The business's revenue for the quarter was up 9.5% compared to the same quarter last year. During the same period in the prior year, the company posted $4.80 earnings per share.
Read the conference call transcript
.

How often does McKesson pay dividends? What is the dividend yield for McKesson?

McKesson declared a quarterly dividend on Monday, July 25th. Shareholders of record on Thursday, September 1st will be given a dividend of $0.54 per share on Monday, October 3rd. This represents a $2.16 annualized dividend and a yield of 0.60%. The ex-dividend date of this dividend is Wednesday, August 31st. This is a positive change from the stock's previous quarterly dividend of $0.47.
Read our dividend analysis for MCK
.

Is McKesson a good dividend stock?

McKesson (NYSE:MCK) pays an annual dividend of $1.88 per share and currently has a dividend yield of 0.54%. The company has been increasing its dividend for 16 consecutive years, indicating the company has a strong committment to maintain and grow its dividend. The dividend payout ratio is 19.87%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, MCK will have a dividend payout ratio of 7.36% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for MCK.

How will McKesson's stock buyback program work?

McKesson announced that its board has authorized a share buyback program on Tuesday, February 2nd 2021, which permits the company to buyback $2,000,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to buy up to 6.9% of its stock through open market purchases. Stock buyback programs are generally an indication that the company's management believes its stock is undervalued.

What guidance has McKesson issued on next quarter's earnings?

McKesson issued an update on its FY 2023 earnings guidance on Wednesday, August, 10th. The company provided EPS guidance of $23.95-$24.65 for the period, compared to the consensus estimate of $23.35. The company issued revenue guidance of -.

What is Brian Tyler's approval rating as McKesson's CEO?

220 employees have rated McKesson Chief Executive Officer Brian Tyler on Glassdoor.com. Brian Tyler has an approval rating of 88% among the company's employees.

What other stocks do shareholders of McKesson own?

Based on aggregate information from My MarketBeat watchlists, some companies that other McKesson investors own include Walt Disney (DIS), Johnson & Johnson (JNJ), Gilead Sciences (GILD), CVS Health (CVS), AbbVie (ABBV), Bank of America (BAC), AT&T (T), JPMorgan Chase & Co. (JPM), UnitedHealth Group (UNH) and Home Depot (HD).

What is McKesson's stock symbol?

McKesson trades on the New York Stock Exchange (NYSE) under the ticker symbol "MCK."

Who are McKesson's major shareholders?

McKesson's stock is owned by many different retail and institutional investors. Top institutional investors include Pzena Investment Management LLC (1.69%), Scharf Investments LLC (0.49%), Robeco Institutional Asset Management B.V. (0.47%), Swiss National Bank (0.45%), Sumitomo Mitsui Trust Holdings Inc. (0.30%) and Russell Investments Group Ltd. (0.29%). Insiders that own company stock include Brian S Tyler, Brian S Tyler, Britt J Vitalone, Kevin Emerson, Lori A Schechter, Lori A Schechter, Marie L/Ca Knowles, Nancy Flores, Sundeep G Reddy, Sundeep G Reddy, Thomas L Rodgers, Thomas L Rodgers and Tracy Faber.
View institutional ownership trends
.

How do I buy shares of McKesson?

Shares of MCK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is McKesson's stock price today?

One share of MCK stock can currently be purchased for approximately $358.25.

How much money does McKesson make?

McKesson (NYSE:MCK) has a market capitalization of $51.49 billion and generates $263.97 billion in revenue each year. The company earns $1.11 billion in net income (profit) each year or $9.46 on an earnings per share basis.

How many employees does McKesson have?

The company employs 75,000 workers across the globe.

Does McKesson have any subsidiaries?

The following companies are subsidiares of McKesson: A.L.I. Technologies, AMISYS Managed Care Systems, Abaton.com, Access Health, Biologics, Celesio, CoverMyMeds, D & K Healthcare Resources, Drug Trading Co. Ltd., EN-Chart Scanning Program, Echo, Emendo, Enterprise Systems Inc., HBO & Company, HPR, HealthCom Partners, HealthQx, IMNET Systems, LloydsDirect, MED3000, McKesson Europe AG, McKesson Europe Holdings GmbH & Co. KGaA, McKesson Global Procurement & Sourcing Limited, McKesson International Bermuda IP2A Limited, McKesson International Bermuda IP3A Limited, McKesson Ireland Limited, McKesson Medical-Surgical Holdings Inc., McKesson Medical-Surgical Inc., McKesson Medical-Surgical Supply Chain Services LLP, McKesson Medical-Surgical Top Holdings Inc., McKesson Plasma and Biologics LLC, McKesson Specialty Care Distribution LLC, McKesson UK Finance I Limited, McKesson UK Finance II Limited, McKesson US Finance Corporation, McQueary Brothers, MedVentive, Medcon, MediVation Inc., Medical Specialties Distributors, Medis Health And Pharmaceutical Services, Moore Medical, NDCHealth, Oncology Therapeutics Network, PSS World Medical, Per-Se Technologies, Portico Systems, Practice Partner, RedLine HealthCare, RelayHealth, Rexall, Rosebud Solutions, RxCrossroads, Sterling Medical Services LLC, UDG Healthcare, US Oncology, US Oncology Holdings Inc., US Oncology Inc., United Drug (Wholesale) Limited, United Drug Distributors Ireland Limited, Vantage Oncology, Vivalog Technologies, Well.ca, and peerVue.
Read More

When was McKesson founded?

McKesson was founded in 1833.

How can I contact McKesson?

McKesson's mailing address is 6555 STATE HWY 161, IRVING TX, 75039. The official website for the company is www.mckesson.com. The company can be reached via phone at (972) 446-4800, via email at investors@mckesson.com, or via fax at 415-983-8453.

This page (NYSE:MCK) was last updated on 8/10/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.